Boyle, Andrew J. http://orcid.org/0000-0002-6201-805X
,
Madotto, Fabiana
Laffey, John G.
Bellani, Giacomo
Pham, Tài
Pesenti, Antonio
Thompson, B. Taylor
O’Kane, Cecilia M.
Deane, Adam M.
McAuley, Daniel F.
,
Article History
Received: 17 April 2018
Accepted: 10 August 2018
First Online: 27 October 2018
Ethics approval and consent to participate
: This study is an ancillary analysis of the LUNG SAFE database. All ICUs participating in LUNG SAFE obtained ethical approval, patient consent or ethics committee waiver of consent [CitationRef removed]. No further data were collected for this ancillary analysis.
: Not applicable.
: Prof McAuley reports personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer, funds to his institution from grants from the UK NIHR and others and from GlaxoSmithKline for undertaking bronchoscopy as part of a clinical trial. In addition, Prof McAuley has a patent application issued to his institution. Dr O’Kane reports a travel grant from AstraZeneca and that her spouse has received personal fees from consultancy for GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim, and Bayer. Dr O’Kane’s institution has also received funds from grants from the Northern Ireland Health and Social Care Research and Development office for studies outside of the submitted work. All other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.